Merck and Finnish pharmaceutical company Orion announced that they have jointly exercised an option to convert the ongoing CYP11A1 inhibitor opevesostat (MK-5684/ODM-208) and other candidate drugs targeting CYP11A1 to a global exclusive license for Merck's development and commercialization.
默沙东与Orion宣布将Opevesostat转为默沙东独家许可
Merck and Orion announced that Opevesostat will be exclusively licensed by Merck.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.